LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.18 2.2

Buy Sell

Overview

Share price change

24h

Current

Min

4.03

Max

4.25

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
EPS	-0.47
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+231.78% upside

Market Stats
By TradingEconomics
Market Cap	-26M 229M
Previous open	1.98
Previous close	4.18

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 lis 2025, 22:42 UTC

Market Talk

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21 lis 2025, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

21 lis 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 lis 2025, 21:47 UTC

Market Talk

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21 lis 2025, 21:43 UTC

Market Talk

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21 lis 2025, 20:18 UTC

Market Talk

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21 lis 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21 lis 2025, 19:48 UTC

Market Talk

Precious Metals Fall for the Week -- Market Talk

21 lis 2025, 19:44 UTC

Earnings

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21 lis 2025, 19:37 UTC

Market Talk

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21 lis 2025, 19:27 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

21 lis 2025, 19:27 UTC

Market Talk

Earnings

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21 lis 2025, 19:20 UTC

Market Talk

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21 lis 2025, 18:44 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21 lis 2025, 18:37 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21 lis 2025, 18:34 UTC

Market Talk

Earnings

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21 lis 2025, 18:28 UTC

Earnings

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 lis 2025, 18:03 UTC

Market Talk

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21 lis 2025, 17:24 UTC

Market Talk

Global Equities Roundup: Market Talk

21 lis 2025, 17:24 UTC

Market Talk

Intuit Seen on Path to Increase Growth -- Market Talk

21 lis 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 lis 2025, 17:05 UTC

Market Talk

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21 lis 2025, 16:56 UTC

Market Talk

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21 lis 2025, 16:47 UTC

Market Talk

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21 lis 2025, 16:35 UTC

Acquisitions, Mergers, Takeovers

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21 lis 2025, 16:09 UTC

Earnings

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 lis 2025, 15:59 UTC

Market Talk

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

21 lis 2025, 15:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 lis 2025, 15:23 UTC

Market Talk

Bank of Canada Not Expected to Be Swayed by Canadian Retail Trade Data -- Market Talk

21 lis 2025, 15:17 UTC

Market Talk

Canadian Consumer Spending Softening, But Could Be Worse -- Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

231.78% upside

12 Months Forecast

Average 13.57 USD 231.78%

High 25 USD

Low 8 USD

Based on 9 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.